ICUS Weekly News Monitor 6-28-2018

1.DOTmed, SonoVue approved in China for intravesical use in ultrasonography of the excretory tract to detect vesicoureteral reflux, June 21, 2018, Press release

2.Aunt Minnie, Bracco's SonoVue ultrasound contrast cleared in China, Jun 20, 2018

3.Daily American, Siemens Healthineers Launches Acuson Sequoia to Address Industry Challenges in Ultrasound Imaging, June 22, 2018



SonoVue approved in China for intravesical use in ultrasonography of the excretory tract to detect vesicoureteral reflux

June 21, 2018

Press release

Milan (Italy), June 20, 2018 - Bracco Imaging S.p.A., a global leader in diagnostic imaging, recently announced that its ultrasound contrast agent SonoVue® (sulphur hexafluoride microbubbles) has been the first approved in China for use in ultrasonography of the urinary tract (voiding ultrasonography) for the evaluation of suspected or known vesicoureteral reflux (VUR) in pediatric patients.

VUR is a urinary tract abnormality in neonates, infants and children characterized by retrograde flow of urine from the bladder into the ureter and toward the kidney and represents a common cause of recurrent urinary tract infections and chronic nephropathy in pediatric patients. Voiding cysturethrography and direct radionuclide cystography are the imaging procedures currently used to diagnose VUR, and both require exposure to ionizing radiation.

“This approval of SonoVue® for voiding ultrasonography addresses an important unmet medical need for accurate detection and follow-up of VUR, a frequent cause of urinary tract infections and renal complications in neonates, infants and young children, without exposing them to the potential harmful effects of ionizing radiation,” stated Alberto Spinazzi, MD, Head, Global Medical and Regulatory Affairs, Bracco Group.

“We are particularly proud that, after United States and Europe, now this important indication for our contrast ultrasound agent SonoVue® has been also approved in China,” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “This new indication for SonoVue® reflects our efforts and investments to offer significant clinical benefit by expanding the range of approved clinical indications for contrast enhanced ultrasound in China, one of the most relevant areas of development for Bracco”.

Since 2004, China has been at the forefront of research in contrast enhanced ultrasound, with the development of innovative clinical applications in various clinical scenarios and patient populations. SonoVue® is the ultrasound contrast agent most widely used in clinical studies and routine clinical practice in China, and the first and only approved for use in the pediatric population in this country.


Aunt Minnie

Bracco's SonoVue ultrasound contrast cleared in China

Jun 20, 2018

By staff writers

Contrast developer Bracco Imaging has received clearance from Chinese regulators for the use of its SonoVue (sulphur hexafluoride microbubbles) ultrasound contrast agent in ultrasonography of the urinary tract.

This clinical application of SonoVue is for evaluating suspected or known vesicoureteral reflux (VUR) in neonates, infants, and children. VUR involves the retrograde flow of urine from the bladder into the ureter and toward the kidney.

SonoVue is a second-generation ultrasound contrast agent with approved clinical indications that include cardiac, vascular, liver, and breast imaging in adults, Bracco said.


Daily American

Siemens Healthineers Launches Acuson Sequoia to Address Industry Challenges in Ultrasound Imaging

June 22,2018

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 22, 2018--Siemens Healthineers has announced the launch of its new ultrasound system, the Acuson Sequoia. The new Acuson Sequoia, a general imaging ultrasound system, was developed in response to one of the most prevalent challenges in ultrasound imaging today: the imaging of different sized patients with consistency and clarity. With its new Deep Abdominal Transducer (DAX), a new high-powered architecture, and innovative updates to elastography and contrast-enhanced ultrasound, the new Acuson Sequoia produces penetration up to 40cm. With its powerful architecture and innovative features, the new Acuson Sequoia expands precision medicine by enabling high-resolution imaging that adapts to patients’ size and personal characteristics, contributing to more confident diagnosis.

“Ultrasound imaging has been plagued by variability. Patients’ varied physical characteristics and user-dependent variabilities can impact a clinician’s ability to deliver an accurate diagnosis,” says Robert Thompson, Head of Ultrasound at Siemens Healthineers. “With the new Acuson Sequoia, Siemens Healthineers provides users with a solution that enables real-time imaging for varying patient types, including those with high BMI, without sacrificing image quality and potentially reducing the need for repeat scans and unclear diagnoses.”

Expanding the reach of ultrasound imaging

According to the World Health Organization, 1.9 billion people globally are reported as overweight with 650 million people classified as obese (with a BMI above 30). Because ultrasound imaging relies on the sending and receiving of echo signals to produce images, patients with more adipose tissue are more difficult to image. The deeper an echo signal needs to penetrate, the more attenuation occurs, resulting in image quality degradation. In attempting to overcome these challenges, clinicians have traditionally had to compromise on frame rates, resolution, or penetration of their ultrasound imaging.

In response, Siemens Healthineers built the entirely new Acuson Sequoia system to adapt to the “BioAcoustic Variations” of each patient, characteristics that include tissue density, stiffness, and absorption. The new Acuson Sequoia provides high-resolution InFocus imaging throughout the entire field of view, from the near field to the far field, in real-time. Therefore, there is no need to adjust the focal point of the scan, resulting in faster scan time without compromising frame rates and resolution. The new ultrasound system also offers high resolution color flow, up to three times the sensitivity, 1,3 and up to 20% deeper penetration.

More power for clearer images

In addition to increased rates of obesity, prevalence of liver disease is also on the rise. 1, 5 Clinicians utilize ultrasound elastography to determine shear wave speed, a parameter correlated with tissue stiffness in the liver which can correlate to chronic disease progression. Imaging in these patients can be challenging, particularly in larger patients where the signals are attenuated. The innovative power architecture of the new Acuson Sequoia provides six times the energy capacity available for shear wave elastography, enabling imaging at greater depths and a reduction in image variability.

The BioAcoustic technology of Acuson Sequoia also improves Contrast Enhanced Ultrasound (CEUS) bubble longevity. Contrast enhanced ultrasound uses microbubble-based contrast agents to improve the visualization and assessment of lesions. With the new Acuson Sequoia system, the view time of contrast agents is significantly longer, allowing clinicians more time to scan for additional incidental lesions during their examinations and with up to twice the sensitivity.

Improving workflows with user-centric technologies

As the most widely used medical imaging modality, 6 ultrasound scanning preferences vary from user to user, making it a highly-personal experience. In a collective effort to eliminate variability and long-term ergonomic injuries, Siemens Healthineers hosted 170 workshops with 365 worldwide ultrasound users to create a platform designed by the user, for the user. The new Acuson Sequoia improves workflow by introducing user-friendly features, such as gesture detecting transducers – activated by touch, automated protocols, and streamlined registration which adapts to user preferences over time. A new ergonomically designed InTune transducer family reduces operator stress while increasing comfort.

A unique new capability among diagnostic ultrasound systems, “UltraArt” provides several image choices which are automatically generated with a user’s preferred image parameter settings, right on the touch screen. The user can select the image that best matches the patient’s BioAcoustic characteristics, avoiding manual adjustment of multiple individual image parameters.

The new Acuson Sequoia offers innovative technologies, unique transducers, and user-defined features to enhance workflow and personalize medicine.

For more information on the new Acuson Sequoia ultrasound system,

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:






Contact ICUS

  • Address:  International Contrast Ultrasound Society
    c/o Dentons
    233 S. Wacker Drive, Suite 5900 Chicago, IL 60606-6361
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News Monitors ICUS Weekly News Monitor 6-28-2018